Tofacitinib for the treatment of psoriasis and psoriatic arthritis.

Tofacitinib is a novel oral janus kinase (JAK) inhibitor approved for the treatment of psoriatic arthritis. It was also investigated for the treatment of plaque psoriasis, although it is not approved by the Food and Drug Administration for this indication. This article aims to summarize the efficacy and safety data of tofacitinib for treatment of psoriatic disease. A comprehensive review of literature was conducted on the PubMed database using the search terms: "((tofacitinib) AND (psoriasis)) OR ((tofacitinib) AND (psoriatic arthritis))". Data from the pivotal clinical trials evaluating tofacitinib in the treatment of psoriatic disease were summarized. The Oral-treatment Psoriasis Trial (OPT) study series demonstrated that tofacitinib is efficacious in the treatment of plaque psoriasis with an acceptable safety profile. The OPT studies also demonstrated the non-inferiority of tofacitinib 10mg twice daily compared to etanercept. The Oral Psoriatic Arthritis triaL (OPAL) study series demonstrated that tofacitinib significantly improved psoriatic arthritis outcomes compared to placebo and had an acceptable safety profile. Its efficacy is comparable to adalimumab in psoriatic arthritis. Patients treated with tofacitinib should be monitored for herpes zoster, malignancies, blood clots, and changes in laboratory values. Overall, tofacitinib is a useful new systemic agent in the treatment of psoriatic disease. Its oral route of administration, novel JAK pathway target, short half-life, and strong recapture rates after treatment interruption make it a unique new tool for psoriatic disease management. Further long-term studies will help determine its role in the treatment algorithm for psoriatic arthritis and its indication for plaque psoriasis.

[1]  P. Sève,et al.  JAK inhibitors for the treatment of autoimmune and inflammatory diseases. , 2019, Autoimmunity reviews.

[2]  D. Gladman,et al.  Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long‐Term Extension Studies , 2019, Arthritis care & research.

[3]  A. Adebajo,et al.  An evaluation of tofacitinib for the treatment of psoriatic arthritis , 2019, Expert opinion on pharmacotherapy.

[4]  N. Mehta,et al.  Cardiovascular Diseases in Psoriasis and Psoriatic Arthritis , 2019, The Journal of Rheumatology. Supplement.

[5]  P. Taylor.  Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis , 2019, Rheumatology.

[6]  A. Gottlieb,et al.  Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta‐analysis of observational and clinical studies , 2019, Journal of the American Academy of Dermatology.

[7]  L. Coates,et al.  SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study , 2018, Saturday, 16 JUNE 2018.

[8]  N. Shear,et al.  A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study , 2017, Journal of the American Academy of Dermatology.

[9]  J. Gómez-Reino,et al.  Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis. , 2017, Seminars in arthritis and rheumatism.

[10]  J. Yeung,et al.  Diagnosis and management of psoriasis. , 2017, Canadian family physician Medecin de famille canadien.

[11]  S. John,et al.  A systematic review of worldwide epidemiology of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[12]  M. González-Gay,et al.  Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. , 2016, Seminars in arthritis and rheumatism.

[13]  P. Mease,et al.  Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study , 2016, The Journal of Rheumatology.

[14]  Robert Wolk,et al.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. , 2016, Journal of the American Academy of Dermatology.

[15]  J. D. Clark,et al.  The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. , 2016, Clinical and experimental rheumatology.

[16]  M. Lebwohl,et al.  US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey , 2015, American Journal of Clinical Dermatology.

[17]  G. Girolomoni,et al.  Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) , 2015, The British journal of dermatology.

[18]  A. Gottlieb,et al.  Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo‐controlled, phase III trials , 2015, The British journal of dermatology.

[19]  S. Chimenti,et al.  Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). , 2015, Journal of the American Academy of Dermatology.

[20]  A. Kavanaugh,et al.  Psoriatic arthritis: latest treatments and their place in therapy , 2015, Therapeutic advances in chronic disease.

[21]  L. Iversen,et al.  Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial , 2015, The British journal of dermatology.

[22]  M. Lebwohl,et al.  Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[23]  H. Yamanaka,et al.  Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis , 2014, Arthritis & rheumatology.

[24]  N. Jourabchi,et al.  The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  M. Lebwohl,et al.  Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. , 2014, Journal of the American Academy of Dermatology.

[26]  Yoshiya Tanaka,et al.  Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. , 2014, Rheumatology.

[27]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[28]  B. Strober.  Methotrexate and cyclosporine in psoriasis revisited. , 2014, Seminars in cutaneous medicine and surgery.

[29]  J. Koo,et al.  Biologic fatigue in psoriasis , 2014, The Journal of dermatological treatment.

[30]  H. Nakagawa,et al.  Risk of herpes zoster in psoriatic patients undergoing biologic treatment , 2014, The Journal of dermatology.

[31]  A. Gottlieb,et al.  Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, , 2014, Annals of the rheumatic diseases.

[32]  Massimo Gadina,et al.  Jakpot! New small molecules in autoimmune and inflammatory diseases , 2014, Experimental dermatology.

[33]  Yeong-Wook Song,et al.  Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study* , 2013, Annals of the rheumatic diseases.

[34]  M. Lebwohl,et al.  Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. , 2013, JAMA dermatology.

[35]  A. Gottlieb,et al.  Continuous versus intermittent therapy for moderate-to-severe psoriasis. , 2013, Clinical and experimental rheumatology.

[36]  E. Sasso,et al.  Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[37]  A. Troxel,et al.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. , 2013, Journal of the American Academy of Dermatology.

[38]  K. Fox,et al.  Treatment Patterns in the First Year After Initiating Tumor Necrosis Factor Blockers in Real-World Settings , 2012, Advances in Therapy.

[39]  A. Armstrong,et al.  Off-Label Biologic Regimens in Psoriasis: A Systematic Review of Efficacy and Safety of Dose Escalation, Reduction, and Interrupted Biologic Therapy , 2012, PloS one.

[40]  Y. Hayami,et al.  The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis , 2012, International journal of rheumatology.

[41]  L. Skov,et al.  Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris , 2011, The British journal of dermatology.

[42]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[43]  J. Ortonne,et al.  Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy , 2011, The British journal of dermatology.

[44]  W. Weger.  Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents , 2010, British journal of pharmacology.

[45]  S. Feldman,et al.  Conversations on psoriasis – what patients want and what physicians can provide: A qualitative look at patient and physician expectations , 2010, The Journal of dermatological treatment.

[46]  A. Finlay,et al.  British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009 , 2009, The British journal of dermatology.

[47]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[48]  J. Saurat,et al.  Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) , 2007, The British journal of dermatology.

[49]  L Naldi,et al.  Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks , 2005, The British journal of dermatology.

[50]  D. Gladman,et al.  Psoriatic arthritis: epidemiology, clinical features, course, and outcome , 2005, Annals of the rheumatic diseases.

[51]  F. Camacho,et al.  Better medication adherence results in greater improvement in severity of psoriasis , 2004, The British journal of dermatology.

[52]  J. Youn,et al.  The Efficacy of Calcipotriol + Acitretin Combination Therapy for Psoriasis , 2003, American journal of clinical dermatology.